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Vitamin D deficiency is endemic in hospitalized patients with multiple myeloma and can predispose to many serious complications. Deficiency can cause osteomalacia and those patients can develop generalized musculoskeletal pain, proximal muscle weakness and increased risk of falls. In many cases, this may not be clinically detectable but are nonetheless present, or "subclinical", and often go unrecognized.

Case Report {#sec1-2}
===========

In June 2010, a 63 year old male with multiple myeloma presented with multiple falls and reactivation of herpes zoster. The patient was previously diagnosed with solitary plasmacytoma in 2001, which then progressed to smoldering myeloma in 2004. In 2007 the indolent version of his myeloma transformed to a more aggressive form of myeloma with non-specific musculoskeletal chest pain, anorexia, weight loss, and tumour-lysis requiring hospital admission and plasmapheresis. The patient was treated by Vincristine, Adriamycin, Dexamethasone and completed six induction cycles with an autologous stem cell transplant in June 2008 with high dose Melphalan. In 2009, the patient was treated with Lenalidomide and Dexamethasone salvage; however his disease was resistant to most standard immonumodulatory agents. Salvation presented itself in the form of a phase II study in investigating the role of Bortezomib with a new agent Vorinostat a histone deacetylase inhibitor in heavily pre-treated myeloma. The patient began therapy with Bortezomib in early march 2010. However, in June 2010 the patient was admitted after multiple falls and zoster reactivation including ophthalmic zoster of the right first and second trigeminal branches.

Despite of all the above management, there was a continuing downturn in his overall performance status over the period of 1 to 2 years with generalized musculoskeletal pain, worse on activity and weight bearing, and muscle weakness. His overall functional ability deteriorated markedly such that he became a major falls risk and suffered four falls whilst in hospital.

On examination he was pale with a depressed affect. The patient had resting tremor, generalized bony tenderness (worse on movement and weight bearing), muscle weakness, and a waddling gait. His bone studies showed features of osteomalacia with an elevated alkaline phosphatase at 270 U/L, very low Vitamin D level of less than 20 nmol/L, and a high intact parathyroid hormone at 16.0 pmol/L.

The patient was commenced on 3000 units of Vitamin D supplementation and physiotherapy. After 4 months, although his multiple myeloma deteriorated, there was a significant decrease in his generalized musculoskeletal pain. His bloods showed a normalized level of Vitamin D of 109 nmol/L and decrease in alkaline phosphatase to 182 U/L. He is currently undergoing palliative rehabilitation.

Discussion {#sec1-3}
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Multiple myeloma is a malignant proliferation of plasma cells producing a monoclonal paraprotein and it is associated with end-organ .The cells may cause soft-tissue masses (plasmacytomas) and/or lytic lesions in the skeleton and they impair humoral and cell-mediated immunity\[[@ref1][@ref2]\]. Skeletal complications are a major cause of morbidity in multiple myeloma (MM). These complications include hypercalcemia due to increased bone resorption, generalized bone loss, intractable bone pain. This is due to the lytic bone destruction as a consequence of an increase in osteoclastic lesions, and pathologic fractures at skeletal sites compromised by osteolytic lesions\[[@ref1]\]. Bone pain is a common presentation in patients with multiple myeloma, particularly in the back or chest, and less often in the extremities, in approximately 60 percent of patients\[[@ref2]\]. The pain is usually induced by movement and does not occur at night except with change of position. The patient\'s height may be reduced by several inches because of vertebral collapse\[[@ref1]--[@ref3]\].

Vitamin D deficiency is extremely common in multiple myeloma, with 40% of patients having vitamin D levels in the deficient range of levels less than 36 nmol/L and it represents a surrogate for clinical multiple myeloma disease status\[[@ref3][@ref4]\]. Vitamin D and its metabolites have a significant clinical role in these patients because of their interrelationship with calcium homeostasis and bone metabolism and it is best measured using the serum 23-hydroxyvitamin D assay\[[@ref5]\].

It is well known that adequate vitamin D intake is essential for healthy bones by helping to maintain calcium and phosphorus homeostasis\[[@ref6]\]. There are two main forms of vitamin D: vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). Vitamin D~3~ is formed in the skin, after exposure to ultraviolet B radiation, from dehydrocholesterol that resides in the cell membranes. Vitamin D2 is obtained through irradiation of ergosterol in plants, and enters human circulation through our diet (i.e., animal sources such as deep sea fatty fish, egg yolks, or liver). Few foods naturally have substantial vitamin D content, and dietary vitamin D is obtained is mainly obtained through fortified foods or supplements. Vitamin D (either D2 or D3) is converted to 23-hydroxyvitamin D in the liver and subsequently to the active form 1,23-dihydroxyvitamin D in the in the kidneys\[[@ref5][@ref6]\]. The synthesis of vitamin D and its metabolism to 1,23(OH)2-Vitamin D is closely coupled to calcium homeostasis, and is modulated by parathyroid hormone, serum calcium, and phosphorus levels. Moderate vitamin D deficiency can cause a decrease in intestinal calcium absorption and an increase in PTH. PTH activates osteoblasts, which stimulate the transformation of preosteoclasts into mature osteoclasts. These cells dissolve the mineralized collagen matrix in bone, causing osteoporosis and increasing the risk of fracture\[[@ref7]\].

Vitamin D deficiency causes musculoskeletal pain\[[@ref7]\]. It is presumed to begin with hypocalcemia, which stimulates parathyroid hormone secretion and sets in motion a cascade of biochemical reactions negatively affecting bone metabolism. An increase in the parathyroid hormone can diminish bone density (osteopenia) and/or more severely affect bone architecture (osteoporosis) and can lead to osteomalacia which generates pain in the periosteal tissues covering the skeleton\[[@ref5][@ref7]\]. This explains why many patients with vitamin D deficiency may complain of dull, persistent, generalized musculoskeletal aches and pains. Myopathy also is part of the osteomalacic complex, fatigue or decrease in muscle strength, usually in lower limbs, may appear prior to any pain. In many cases involving pain and myopathy, defects of bone metabolism and osteomalacia may not be clinically detectable but are nonetheless present, or "subclinical"\[[@ref2][@ref7]\].

Vitamin D deficiency is also common among hospitalized patients\[[@ref8]\], and it is evident that people over age 63 years with low serum 23-hydroxyvitamin D concentrations (\<23 nmol/L) are at greater risk for loss of muscle strength and muscle mass and for hip fractures\[[@ref9]\]. Muscle biopsy in such people revealed atrophy of the fast twitch (type II) fibers. As type II fibers are first to be recruited to avoid falling, this observation may explain the increased falls risk in vitamin D deficient individuals\[[@ref10]\].

Vitamin D supplementation may contribute to improved bone mineral density and muscle function and has shown to reduce falls risk by more than 20% and concentrations less than 40 nmol/L is associated with substantially poorer leg function\[[@ref11][@ref12]\]. The fracture reduction is correlated with the dose of vitamin D, such that doses less than 800 IU are not effective\[[@ref13][@ref14]\]. A randomized trial found a 30 percent reduction in fall incidence over five months comparing subjects taking placebo with those taking vitamin D 800 IU daily\[[@ref13]\]. These observations suggest that, if used to prevent falls, the daily intake of standard supplemental vitamin D in older adults should be at least 700 to 800 IU and lower intakes of vitamin D are not as effective\[[@ref13][@ref14]\].

While the daily requirement for vitamin D is 400--600 IU, a larger dose is needed to treat patients with deficiency. Larger doses of vitamin D are needed before a change in serum 23-OHD levels is seen\[[@ref14]\]. This is due to the fact that vitamin D is distributed in the body fat compartment, which is larger than the plasma and extracellular fluid compartment. This may explain the delay seen with vitamin D supplements before normalization of serum 23-OHD levels. In moderate to severe deficiency supplementation with 3000-5000 IU (73--123 μg) per day for at least 6--12 weeks may be required followed by a maintenance dose of 1000 to 2000 IU to maintain normal physiological needs in otherwise healthy individuals\[[@ref14]\]. In addition to falls reduction, there is evidence that vitamin D modulates several other critical cellular processes, including inhibition of carcinogenesis by induction of differentiation, inhibition of proliferation and angiogenesis, and promotion of apoptosis\[[@ref10]\], and an increase of 23 nmol/L in 23-hydroxy-vitamin D levels was associated with a 17 percent lower multivariate total cancer risk\[[@ref15]\].
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This case highlights that vitamin D deficiency is common in patients with multiple myeloma, and can cause generalized musculoskeletal pain and increase the risk of falls, yet it often goes unrecognized. Vitamin D deficiency is also common in hospitalized patients and can have numerous negative effects on their well-being and recovery leading to prolonged hospital stay. Therefore, in patients with non-specific musculoskeletal pain, and inadequate sun-exposure physicians and general practitioners must have a high index of suspicion for vitamin D deficiency.
